Topic resource collection
Approved comparison material connected to this topic.
12 resourcesRead both sides
The following table summarizes dosage ranges, administration routes, and endpoints from published PE-22-28 research. Use this as a reference for designing your own protocols—but remember that dose-response relationships observed …
1mg/kg daily 12–15% ~40% MC4R Once daily subcutaneous Minimal effect on dentate gyrus proliferation markers; subtherapeutic for most neurogenic endpoints Too low. Insufficient receptor engagement to sustain CREB phosphorylation a…
Rodent elevated plus maze (2020 Neuropeptides study) 1–3mg/kg subcutaneous Subcutaneous injection 30–60 minutes post-dose 2–4 hours 1mg/kg produced statistically significant anxiety reduction without ceiling effect at 3mg/kg. Opt…
Acute single-dose studies using PE-22-28 demonstrate rapid TREK-1 blockade within 30–60 minutes post-injection, but behavioural antidepressant effects require repeated administration over 7–28 days. This delay mirrors clinical an…
| Dosage Protocol | Administration Route | Frequency | Observed BDNF Elevation | Behavioural Efficacy (FST Immobility Reduction) | Recommended Use Case | Professional Assessment ||—|—|—|—|—|—|| 0.1 mg/kg | Subcutaneous | Daily × …
Depression behavior (FST, TST) 1 mg/kg Intraperitoneal 60 minutes Reduced immobility time, increased TREK-1 surface expression Gold standard dose. Most reproducible across labs and strains Ischemic stroke (MCAO model) 2–3 mg/kg I…
5mg 1mL 5mg/mL (5,000mcg/mL) 0.05mL (5 units) 0.1mL (10 units) 20 doses (250mcg) or 10 doses (500mcg) Best for low-dose protocols. Smallest injection volumes, highest precision on standard syringes 2mL 2.5mg/mL (2,500mcg/mL) 0.2m…
PE-22-28 Research peptide only. No FDA approval No Phase I trials published; rodent doses 0.5–5 mg/kg Available through research suppliers; not for human use IRAP inhibition → increased BDNF, hippocampal neurogenesis Promising pr…
Standard Neuroplasticity 300–400 mcg Morning (within 2h of waking) 28 days on, 14 days off Detectable increase by day 10–14 Optimal for first-time researchers. Balances efficacy with tolerability and allows clear assessment of re…
Acute Cognitive Enhancement 10–15mg Single dose 60–90 min pre-task Learning consolidation, spatial memory testing Effects measurable 2–6 hours post-dose Best for isolated cognitive tasks; not sustained neuroplasticity Chronic Neu…
Neuroprotection (stroke) 10–15mg/kg IV bolus 4–6μM Single dose 42% infarct reduction at 12mg/kg within 60min of occlusion Narrow therapeutic window. Dose-timing critical Cardiac arrhythmia 15–20mg/kg IV infusion 6–8μM sustained 4…
Different reconstitution volumes create different concentrations from the same peptide mass, changing the injection volume required to deliver identical doses. Choose reconstitution volume based on your subject size and target do…